血清CEA水平与EGFR-TKI治疗晚期非小细胞肺癌的预后相关性分析

目的探讨血清CEA水平与表皮生长因子受体络氨酸激酶受体抑制剂(EGFR-TKI)治疗晚期非小细胞肺癌的预后相关性。方法对121例晚期非小细胞肺癌患者采用EGFR-TKI药物吉非替尼进行治疗,并在接受治疗前进行血清CEA水平的检测,同时对患者的预后与患者的性别、年龄、癌变类型以及CEA水平等进行分析,并以50μg/L为分界线,将患者分为高CEA水平组以及低CEA水平组。结果对2组患者不良反应以及症状主要以皮疹、厌食、恶心、腹泻以及呕吐为主,2组患者比较无统计学差异性。对2组患者治疗疗效比较,高CEA水平组患者其有效率为32.4,稳定为40.8%以及恶化为26.8%,而低CEA水平组患者分别为20%、20%以及60%,2组患者治疗疗效差异有统计学意义(P<0.05)。对患者进行生存分析结果提示,高CEA水平患者其经过吉非替尼治疗后有更长的无疾病进展时间以及生存时间(P<0.05)。结论血清CEA水平可作为评估吉非替尼治疗晚期非小细胞肺癌的疗效以及预后的生化指标。

The correlation between the serum levels of CEA and patient's prognosis after EGFR-TKI treatment in patients with advanced non-small cell lung cancer

Objective To investigate the correlation between the serum levels of carcinoembryonic antigen （CEA） and patient＇s prognosis after EGFR-TKI （gefitinib） treatment in patients with advanced non-small cell hmg cancer. Methods 121 patients with advanced non-small cell lung cancer were treated by EGFR-TKI drugs-gefitinib,and the serum levels of CEA in the patients were detected before treatment, and the correlation between patients＇ prognosis and patients＇ gender,age, cancer types, and CEA levels were analyzed. With 50 Ixg/L as dividing line, the patients were divided into high CEA level group and low CEA level group. Results The adverse reactions and clinical symptoms in both groups were mainly rash, anorexia, nausea, diarrhea and vomiting, however,there were no significant differences in these parameters between the two groups. The effective rate, stabilization rate,deterioration rate in,high CEA level group were 32.4 （23/71） ,40.8% （29/71） ,26.8% （19/ 71） ,respectively,however,which in low CEA level group were 20% （10/50）,20% （10/50）,60% （30/50）, respectively, there were significant differences between two groups （ P 〈 0.05 ）. The analysis results for patient＇ s survival suggested that after gefitinib treatment the patients in high CEA level group had longer disease-free advancement time and survival time, as compared witgh those in low CEA level group （ P 〈 0.05）. Conclusion The serum levels of CEA can be used as the biochemical indicator for evaluating the therapeutic effect of gefitinib on advanced non-small cell lung cancer and the patients＇ prognosis.